NCT05230914

Brief Summary

Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy. The newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP/MRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,846

participants targeted

Target at P75+ for not_applicable

Timeline
18mo left

Started Dec 2024

Typical duration for not_applicable

Geographic Reach
1 country

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
Dec 2024Oct 2027

First Submitted

Initial submission to the registry

January 27, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 9, 2022

Completed
2.8 years until next milestone

Study Start

First participant enrolled

December 12, 2024

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2027

Last Updated

December 26, 2025

Status Verified

December 1, 2025

Enrollment Period

2.5 years

First QC Date

January 27, 2022

Last Update Submit

December 18, 2025

Conditions

Keywords

endovascular treatmentlarge vessel occlusionacute ischemic strokecomputed tomography perfusionnon-contrast computed tomographyAlberta Stroke Program Early CT score

Outcome Measures

Primary Outcomes (1)

  • favorable outcome at 90 days

    defined as modified Rankin scale score of 0 to 3. Modified Rankin scale score (mRS): scores range from 0 to 6, with 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.

    90 days post-endovascular treatment

Secondary Outcomes (2)

  • symptomatic intracranial hemorrhage within 48 hours

    within 48 hours post-endovascular treatment

  • mortality at 90 days

    90 days post-endovascular treatment

Study Arms (2)

Simple imaging

EXPERIMENTAL

NCCT and CTA will be used to screen patients for endovascular treatment

Other: Simplified imaging strategy

Standard imaging

ACTIVE COMPARATOR

NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment

Other: Standard imaging strategy

Interventions

NCCT and CTA will be used to screen patients for endovascular treatment

Simple imaging

NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment

Standard imaging

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18 years or older;
  • The interval time from last known well to hospital arrival is within 24 hours;
  • Acute stroke confirmed by clinical symptoms or imaging examination;
  • Field Assessment Stroke Triage for Emergency Destination (FAST ED) ≥4;
  • Written informed consent is obtained from patients and/or their legal representatives.

You may not qualify if:

  • Allergy to radiographic contrast agents, or nitinol devices;
  • Currently pregnant or lactating (women patients);
  • Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
  • Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
  • Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
  • Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
  • Intracranial aneurysm, arteriovenous malformation;
  • Any terminal illness with life expectancy less than 6 months;
  • Unlikely to be available for 90-day follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Yijishan Hospital of Wannan Medical College

Wuhu, Anhui, 241000, China

RECRUITING

Xinqiao Hospital of Army Medical University

Chongqing, Chongqing Municipality, 400037, China

NOT YET RECRUITING

Wuyi Traditional Chinese Medicine Hospital

Jiangmen, Guangdong, 529000, China

NOT YET RECRUITING

The First Affiliated Hospital of Hainan Medical University

Haikou, Hainan, 570000, China

RECRUITING

Huai'an First People's Hospital

Huai'an, Jiangsu, 223001, China

RECRUITING

The 904th Hospital of CPLA

Wuxi, Jiangsu, 214000, China

NOT YET RECRUITING

Jingdezhen First People's Hospital

Jingdezhen, Jiangxi, 333000, China

RECRUITING

Dalian Central Hospital

Dalian, Liaoning, 116000, China

RECRUITING

MeSH Terms

Conditions

Ischemic StrokeStroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 27, 2022

First Posted

February 9, 2022

Study Start

December 12, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

October 31, 2027

Last Updated

December 26, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

study data without patient information

Shared Documents
STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
Time Frame
Related papers published 6 months later, the IPD will be shared
Access Criteria
yangqwmlys@163.com

Locations